Paradigm Biopharmaceuticals Limited (ASX:PAR) is an ASX-listed biotechnology company focused on repurposing Pentosan Polysulfate Sodium (PPS), an FDA approved drug that has a long track record of safely treating inflammation over 60 years. The Company’s primary focus is on repurposing PPS (under the name ZILOSUL®) to treat Osteoarthritis (OA) – a market with over 31m sufferers in the USA alone.
More details about our programme can be found here.
Current shareholders click here to access and update your personal details.
Paradigm is thrilled to welcome new members to our team, consolidating and strengthening the depth of expertise and experience that has driven the success of our clinical programmes to date.
Sharon Charles – Global Head, Clinical Development
Michelle Coffey – Global Head, Regulatory Affairs
Karla Knower – Associate Director, Regulatory Affairs
Jill Forrest – Project Manager, Clinical Operations
For additional details, please see our ASX announcement.